Pacific Biosciences of California (PACB)

Currency in USD
1.150
0.000(0.00%)
Closed·
1.160+0.010(+0.87%)
·
PACB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.1251.180
52 wk Range
1.0702.730
Key Statistics
Prev. Close
1.15
Open
1.15
Day's Range
1.125-1.18
52 wk Range
1.07-2.73
Volume
3.93M
Average Volume (3m)
6.48M
1-Year Change
-12.2137%
Book Value / Share
-0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PACB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.292
Upside
+99.28%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Analyst Ratings

4 Buy
2 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2.292
(+99.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Sell1.50+30.43%1.00MaintainMay 11, 2026
Barclays
Sell1.00-13.04%1.50MaintainApr 15, 2026
Canaccord
Buy3.00+160.87%-MaintainMar 19, 2026
Barclays
Sell1.50+30.43%-DowngradeMar 06, 2026
Canaccord Genuity
Buy3.00+160.87%-MaintainJan 26, 2026

Pacific Biosciences of California SWOT Analysis


Genomics Headwinds
PacBio faces challenges in the genomics industry, with revised guidance reflecting slower sales cycles and macroeconomic pressures on its Revio system placements
Financial Resilience
Explore PacBio's ambitious $75 million cost-out run-rate target and its goal to achieve free cash flow positivity by 2026, showcasing strategic financial management
Market Dynamics
Delve into the complex interplay of macroeconomic factors, capital expenditure trends, and PacBio's innovative commercial strategies in the evolving genomics secto
Analyst Perspectives
Barclays Capital Inc. sets price targets ranging from $2.00 to $3.00, reflecting cautious optimism amidst PacBio's efforts to navigate market challenges
Read full SWOT analysis

Pacific Biosciences of California Earnings Call Summary for Q2/2026

  • PacBio Q2 revenue of $39M missed estimates by 4.15%; adjusted loss of $0.14/share wider than expected $0.13, driving stock down 11.8%
  • Company slashed FY2026 revenue guidance to $155M-$165M and delayed cash flow breakeven target from 2027 to 2028 amid slower adoption
  • Consumables revenue rose 6% YoY and EMEA surged 52%, but instrument revenue fell 9% due to lower pricing and reduced Vega shipments
  • New CEO Mark Van Oene emphasized SPRQ-Nx chemistry rollout to improve economics and compete for larger projects despite slow initial adoption
  • Company announced restructuring cutting 40 employees to save $15M-$20M in 2027; cash balance expected to decline to $175M-$185M by year-end
Last Updated: 08/06/2026, 05:32 AM
Read Full Transcript

Earnings

Latest Release
Aug 05, 2026
EPS / Forecast
-0.14 / -0.13
Revenue / Forecast
39M / 40.69M
EPS Revisions
Last 90 days

PACB Income Statement

Compare PACB to Peers and Sector

Metrics to compare
PACB
Peers
Sector
Relationship
P/E Ratio
−2.7x−0.7x−0.4x
PEG Ratio
−0.040.050.00
Price/Book
−10.8x2.1x2.6x
Price / LTM Sales
2.2x1.9x3.1x
Upside (Analyst Target)
117.4%16.3%47.9%
Fair Value Upside
Unlock5.0%6.3%Unlock

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
116.65M37.56%134.15M
Other Institutional Investors
72.44M23.32%83.30M
Public Companies & Retail Investors
121.52M39.12%139.75M
Total
310.6M100.00%357.19M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
ARK Investment Management LLC11.68%36,273,28841,714
BlackRock, Inc.10.41%32,339,55037,190

People Also Watch

140.00
SPCX
-0.91%
44.38
OKLO
-4.46%
80.250
RKLB
+0.19%
282.50
CEG
+1.39%
21.170
QBTS
+1.29%

FAQ

What Is the Pacific Biosciences (PACB) Stock Price Today?

The Pacific Biosciences stock price today is 1.150 USD.

What Stock Exchange Does Pacific Biosciences Trade On?

Pacific Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Pacific Biosciences?

The stock symbol for Pacific Biosciences is "PACB."

What Is the Pacific Biosciences Market Cap?

As of today, Pacific Biosciences market cap is 357.460M USD.

What Is Pacific Biosciences's Earnings Per Share (TTM)?

The Pacific Biosciences EPS (TTM) is -0.431.

When Is the Next Pacific Biosciences Earnings Date?

Pacific Biosciences will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is PACB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Pacific Biosciences Stock Split?

Pacific Biosciences has split 0 times.

How Many Employees Does Pacific Biosciences Have?

Pacific Biosciences has 485 employees.

What is the current trading status of Pacific Biosciences (PACB)?

As of Aug 17, 2026, Pacific Biosciences (PACB) is trading at a price of 1.150 USD, with a previous close of 1.150 USD. The stock has fluctuated within a day range of 1.125 USD to 1.180 USD, while its 52-week range spans from 1.070 USD to 2.730 USD.

What Is Pacific Biosciences (PACB) Price Target According to Analysts?

The average 12-month price target for Pacific Biosciences is 2.292 USD, with a high estimate of 3 USD and a low estimate of 1.25 USD. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +99.28% Upside potential.

What Is the PACB Premarket Price?

PACB's last pre-market stock price is 1.159 USD. The pre-market share volume is 28,760.000, and the stock has decreased by 0.009, or 0.780%.

What Is the PACB After Hours Price?

PACB's last after hours stock price is 1.160 USD, the stock has decreased by 0.010, or 0.870%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.